Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$1.71 USD
-0.06 (-3.12%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.74 +0.03 (1.75%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPTX 1.71 -0.06(-3.12%)
Will RPTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for RPTX
1,2,3 Pullback Bullish appears for RPTX after 3.12% move
Technical picture remains unchanged for RPTX after it rises 1.44% on September 19
Sideways movement on September 17 results in no shift to RPTX’s technical outlook
RPTX's price falls by 1.42% on September 16, though its technical setup remains stable.
NR7 appears for RPTX after 0.28% move